Live Chat

I CFD sono strumenti complessi e presentano un alto rischio di perdere soldi rapidamente a causa della leva finanziaria. Il 74% dei conti di clienti al dettaglio perde denaro facendo trading con i CFD con questo fornitore. Devi verificare se comprendi pienamente come funzionano i CFD e se puoi permetterti di correre il rischio elevato di perdere i tuoi soldi.

Close

Fai trading su BioNTech BNTX

Vendi
 Acquista

Grafico live di BioNTech

5m 15m 30m 1h 4h 1d 1w

Fondamentali dello strumento

Weekly Search
Weekly
Daily
Data Chiudi Variazione variazione % Apertura Massimo Minimo

Le ultime notizie

Nvidia Blackwell AI Chips
Markets.com Support Team 2024 Nov 14, 16:00

L’importante rally dei titoli del tech in parte dipenderà dalle trimestrali di Nvidia che verranno pubblicate mercoledì.

Forex Indici
Markets.com Support Team 2024 Nov 07, 16:00

La prossima settimana: Trump trade, dati sull’inflazione e trimestrali di Disney

Forex Indici
US Election 2024, Harris vs Trump
Markets.com Support Team 2024 Oct 31, 16:00

La prossima settimana: Elezioni USA: Trump contro Harris nel duello finale

Forex Indici
Big Tech, Apple, Meta, Microsoft, Amazon & Alphabet
Markets.com Support Team 2024 Oct 24, 16:00

La prossima settimana: Apple in testa nelle trimestrali dei big del tech, manovra finanziaria nel Regno Unito e salariati extra agricoli USA

Forex Indici
Time for Tesla earnings
Markets.com Support Team 2024 Oct 17, 16:00

La prossima settimana:   Preparati per le trimestrali di Tesla

Forex Indici
ECB set to cut rates for the third time this year
Markets.com Support Team 2024 Oct 10, 16:00

La prossima settimana: Previsione di taglii per la BCE mentre la stagione degli utili entra nel vivo a Wall Street

Forex Indici
New Zealand rate cut likely, FOMC and RBA minutes out
Markets.com Support Team 2024 Oct 05, 16:00

La prossima settimana: Pubblicazione verbali FOMC, ulteriori tagli probabili in Nuova Zelanda

Forex Indici
Markets eye Powell speech, nonfarm payrolls for clues on future cuts
Markets.com Support Team 2024 Sep 26, 16:00

La prossima settimana: Mercati in attesa delle dichiarazioni di Powell e dati occupazionali per indizi su un taglio dei tassi a novembre

Forex Indici

Informazioni

Spread

1.0525

Spread (%)

1.0364 %

Leva

1:5

Interesse overnight acquisto

-0.0597 %

Interesse overnight vendita

-0.0292 %

Valuta

USD

Orari di trading

Markets closed

Giovedi

14:31 - 20:59

Lunedì

14:31-20:59

Martedì

14:31-20:59

Mercoledì

14:31-20:59

Venerdì

14:31-20:59

Analisi e statistiche

Apertura

---

Chiusura precedente

---

Massimo/Minimo di 52 settimane

--- – ---

Capitalizzazione di mercato

25508335616

Azioni in circolazione

239740000

Data delle trimestrali (prossima)

0000-00-00

Rendimento da dividendo

2022-06-17

Data ex dividendo

2022-06-02

Tasso di dividendo annuale a termine

0

Rendimento del dividendo annuale a termine

0

EPS

-2.05

Scopri di più su questo strumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Strumenti correlati

Asset
Vendi
Acquista
variazione %

Fai trading ora

Fai trading ora

Fai trading ora

Fai trading ora
Strumenti correlati
Trustpilot
Live Chat